NCT01710631View on ClinicalTrials.gov

Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

PHASE3CompletedINTERVENTIONAL
Enrollment

791

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Primary Insomnia
Interventions
DRUG

eszopiclone 3 mg

eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).

DRUG

placebo

placebo

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01710631 - Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia | Biotech Hunter | Biotech Hunter